Actively Recruiting
Comparing Two Conditioning Regimens Using Fludarabine and Busulfan With or Without Melphalan in Adults With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2025-02-18
222
Participants Needed
9
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two conditioning regimens before allogeneic stem cell transplantation allo-HSCT in adults aged 16 to 55 with acute myeloid leukemia AML or myelodysplastic syndrome MDS. The goal is to compare outcomes using fludarabine combined with either busulfan alone or busulfan plus melphalan. This study aims to assess if adding melphalan lowers relapse rates after transplantation. Participants are randomly assigned to receive one of two drug regimens fludarabine with busulfan and melphalan, or fludarabine with busulfan alone. The doses include fludarabine 150 mgm2, busulfan either 6.4 mgkg with melphalan or 12.8 mgkg without melphalan, and melphalan 140 mgm2 for the combination group. This multi-center trial compares the transplant outcomes between these regimens. During the study, participants will be monitored for disease-free survival over two years as the main outcome. Additional measurements include overall survival, relapse rates, and non-relapse mortality at 100 days and two years post-transplant. The study involves regular follow-up visits and assessments to track treatment effects and safety until June 2026.
CONDITIONS
Brief Title
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Research Team
C
chun Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here